{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.ketanserin","code":"thing-q415997","url":"https://ver.cy/models/thing/q415997/","name":"ketanserin","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Ketanserin is a synthetic quinazoline-derived drug that antagonizes serotonin 5-HT2A receptors and also blocks alpha-1 adrenergic receptors, contributing to its blood-pressure-lowering effects.","purpose":"Enable an agent to identify ketanserin, assess a particular material's fitness for a proposed use, and interpret its pharmacological evidence without conflating chemical identity, receptor effects, and product authorization.","scope":{"in":["Parent ketanserin identity and verified chemical identifiers","Relationships to protonated forms, salts, and isotopically labelled ketanserin","Batch composition, purity, analytical identity, and degradation","Physical properties, dissolution, and storage under specified conditions","Receptor interactions and the experimental limits of pharmacological interpretation","Material-specific hazards and jurisdiction-specific use constraints"],"out":["Finished medicinal products, their excipients, and manufacturing specifications","Patient-specific prescribing, dosing, and treatment decisions","Complete models of serotonin receptors, adrenergic receptors, or cardiovascular disease","Chemical synthesis routes and manufacturing plant operations","Full experimental protocols and laboratory equipment models"],"boundaries":[]},"distinguishingFeatures":["Confirm the quinazoline-2,4-dione structure bearing a 2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl substituent; a similar name or serotonergic effect does not establish identity. [ChEBI](https://www.ebi.ac.uk/chebi/CHEBI%3A6123)","Match the parent compound to CAS 74050-98-9, PubChem CID 3822, and formula C22H22FN3O3, then corroborate the actual sample analytically. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Ketanserin)","Distinguish ketanserin tartrate from the parent compound through counterion composition and material identifiers; PubChem records the tartrate separately as CID 16219944. [PubChem: ketanserin tartrate](https://pubchem.ncbi.nlm.nih.gov/compound/Ketanserin-tartrate)","Check both serotonergic and alpha-adrenergic activity when interpreting an experimental response; ketanserin's activity does not by itself establish a serotonin-specific mechanism. [ChEBI](https://www.ebi.ac.uk/chebi/CHEBI%3A6123)"],"structure":{"bundles":[{"id":"ketanserin-identity-and-forms","name":"Ketanserin identity and forms","description":"Establish the parent entity and preserve meaningful distinctions among materials bearing its name.","layers":[{"id":"parent-structure","name":"Parent structure","description":"Recognize ketanserin by chemical structure and corroborating identifiers.","findings":[{"id":"structure-backed-recognition","name":"Structure-backed recognition","description":"Require agreement between the claimed ketanserin identity, authoritative structure records, and available sample evidence.","questions":[{"text":"Which structure record defines the parent ketanserin entity represented by vr.tr.ketanserin?","id":"structure-backed-recognition-q01","kind":"definition"},{"text":"Which analytical observations support assigning this sample to that structure?","id":"structure-backed-recognition-q02","kind":"measurement"}]}]},{"id":"salt-and-label-boundaries","name":"Salt and label boundaries","description":"Relate supplied forms and derivatives to ketanserin without erasing their composition.","findings":[{"id":"material-form-accounting","name":"Material form accounting","description":"Record counterions, stoichiometry, solvent or water content, and any isotope substitution before transferring parent properties.","questions":[{"text":"Does this material contain neutral ketanserin, a specified ketanserin salt, or an isotopically labelled derivative?","id":"material-form-accounting-q01","kind":"boundary"},{"text":"What composition evidence supports conversion from weighed material to moles of ketanserin?","id":"material-form-accounting-q02","kind":"measurement"}]}]}]},{"id":"ketanserin-batch-quality","name":"Ketanserin batch quality","description":"Determine what a particular ketanserin lot contains and whether its evidence supports the intended use.","layers":[{"id":"analytical-confirmation","name":"Analytical confirmation","description":"Connect the lot to direct identity and content measurements.","findings":[{"id":"identity-and-content-evidence","name":"Identity and content evidence","description":"Separate confirmation of ketanserin identity from quantification of ketanserin content.","questions":[{"text":"Which reference standard and analytical methods establish this lot's ketanserin identity?","id":"identity-and-content-evidence-q01","kind":"provenance"},{"text":"Is the reported purity a mass assay or chromatographic area percentage, and what uncertainty accompanies it?","id":"identity-and-content-evidence-q02","kind":"measurement"}]}]},{"id":"impurities-and-release","name":"Impurities and release","description":"Assess contaminants and the evidence needed to accept a lot for a particular purpose.","findings":[{"id":"use-specific-lot-fitness","name":"Use-specific lot fitness","description":"Judge impurity and residual-solvent results against explicit requirements for the proposed ketanserin application.","questions":[{"text":"Which related substances, residual solvents, or unassigned peaks are present, and at what measured levels?","id":"use-specific-lot-fitness-q01","kind":"measurement"},{"text":"Do the lot's measured attributes satisfy the acceptance criteria for the proposed receptor assay or other use?","id":"use-specific-lot-fitness-q02","kind":"action"}]}]}]},{"id":"ketanserin-physical-state-and-solutions","name":"Ketanserin physical state and solutions","description":"Track properties and changes that determine how much ketanserin remains in a usable material state.","layers":[{"id":"form-dependent-properties","name":"Form-dependent properties","description":"Attach physical measurements to the actual chemical and solid form.","findings":[{"id":"qualified-physical-constants","name":"Qualified physical constants","description":"Require material identity and experimental conditions for thermal, solubility, and ionization measurements.","questions":[{"text":"Which ketanserin form and method underlie each reported melting interval, decomposition observation, or solubility value?","id":"qualified-physical-constants-q01","kind":"provenance"},{"text":"What measured pH, temperature, solvent composition, and equilibration time apply to the solubility result?","id":"qualified-physical-constants-q02","kind":"measurement"}]}]},{"id":"solution-and-storage-condition","name":"Solution and storage condition","description":"Assess prepared ketanserin solutions and stored material at the point of use.","findings":[{"id":"available-concentration-and-stability","name":"Available concentration and stability","description":"Distinguish nominal preparation from verified dissolved concentration and retained chemical integrity.","questions":[{"text":"After dilution into the final assay medium, what evidence establishes dissolved ketanserin concentration and absence of precipitation?","id":"available-concentration-and-stability-q01","kind":"measurement"},{"text":"Which stability data support use after the recorded storage duration, temperature, light exposure, and freeze-thaw history?","id":"available-concentration-and-stability-q02","kind":"action"}]}]}]},{"id":"ketanserin-pharmacological-interpretation","name":"Ketanserin pharmacological interpretation","description":"Represent target interactions and the limits of conclusions drawn from ketanserin experiments.","layers":[{"id":"target-resolved-evidence","name":"Target-resolved evidence","description":"Keep each binding or functional result attached to a defined receptor and experimental system.","findings":[{"id":"binding-versus-functional-blockade","name":"Binding versus functional blockade","description":"Record affinity and functional antagonist evidence separately, with explicit receptor subtype and species.","questions":[{"text":"Which evidence establishes ketanserin activity at 5-HT2A and comparison targets in the species being studied?","id":"binding-versus-functional-blockade-q01","kind":"provenance"},{"text":"Does the reported value measure binding affinity, displacement, or functional antagonism, and under which assay conditions?","id":"binding-versus-functional-blockade-q02","kind":"measurement"}]}]},{"id":"mechanistic-specificity","name":"Mechanistic specificity","description":"Determine how strongly a ketanserin-sensitive response supports a proposed mechanism.","findings":[{"id":"competing-target-explanations","name":"Competing target explanations","description":"Treat receptor specificity as a conclusion requiring concentration-matched evidence and controls.","questions":[{"text":"At the tested ketanserin concentration, could alpha-adrenergic or other target activity explain the observed effect?","id":"competing-target-explanations-q01","kind":"boundary"},{"text":"Which orthogonal antagonist, genetic control, or direct target measurement would distinguish the proposed receptor mechanism?","id":"competing-target-explanations-q02","kind":"action"}]}]}]},{"id":"ketanserin-handling-and-use-status","name":"Ketanserin handling and use status","description":"Connect handling decisions and proposed uses to evidence for the exact material and jurisdiction.","layers":[{"id":"material-hazard-evidence","name":"Material hazard evidence","description":"Identify applicable hazard information for ketanserin in its supplied form and concentration.","findings":[{"id":"form-specific-handling-basis","name":"Form-specific handling basis","description":"Record the SDS source, revision, jurisdiction, classification, and handling instructions without substituting a different salt or formulation.","questions":[{"text":"Which current SDS matches this ketanserin material, and what GHS classification and exposure-limit evidence does it provide?","id":"form-specific-handling-basis-q01","kind":"provenance"},{"text":"What containment, protective equipment, storage, and waste route follow from that evidence and the planned operation?","id":"form-specific-handling-basis-q02","kind":"action"}]}]},{"id":"research-and-medicinal-boundary","name":"Research and medicinal boundary","description":"Separate substance properties from permission to use a particular product for a particular purpose.","findings":[{"id":"dated-use-authorization","name":"Dated use authorization","description":"Attach authorization claims to a named product, jurisdiction, route, indication, and verification date.","questions":[{"text":"Is the proposed use analytical research, an authorized investigation, or use of a licensed medicinal product?","id":"dated-use-authorization-q01","kind":"boundary"},{"text":"Which authoritative record establishes the applicable authorization and restrictions on the date of the proposed use?","id":"dated-use-authorization-q02","kind":"provenance"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of ketanserin this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-kinds","name":"Kinds and varieties","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these kinds and varieties hold for the sense of ketanserin this model covers, and on what evidence?","id":"evidence-kinds-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of ketanserin this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of ketanserin this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-measurements","name":"Typical measurements","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these typical measurements hold for the sense of ketanserin this model covers, and on what evidence?","id":"evidence-measurements-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of ketanserin this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of ketanserin this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Describe ketanserin's receptor actions and its use as a blood pressure drug and research tool.","Note that it is licensed in only some countries."],"mustNot":["Recommend, dose or supply it to a person without a prescriber's decision.","Advise combining it with drugs that prolong the QT interval.","Present research findings as approved clinical uses."],"requiresHuman":["Any decision to start, stop or change treatment."]},"ethics":{"considerations":["Patients need honest information about which uses are proven and which are experimental."],"affectedParties":["Patients","Prescribers","Research volunteers"]},"owners":{"steward":"The marketing authorisation holder where it is licensed; the prescriber answers for each use.","roles":[],"masterSystems":["National medicines registers"]},"relations":[{"target":"Q11173","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.ketanserin","Wikidata: Q415997 (https://www.wikidata.org/wiki/Q415997)"]},"properties":{"applicability":"required","items":["Parent molecular identity: C22H22FN3O3; CAS 74050-98-9; PubChem CID 3822","Parent molar mass: 395.4 g/mol","Chemical form: Neutral parent; protonated species; specified salt; specified solvate or hydrate; unresolved","Identity evidence: Sample linked to reference standard, chromatogram, mass spectrum, and/or NMR assignment","Assay and impurity profile: Mass fraction %; chromatographic area % recorded separately; named impurities and method","Dissolved ketanserin concentration: mol/L or mg/mL; parent-equivalent basis; solvent, pH, temperature, and measurement time","Thermal behavior: Melting interval and decomposition onset in °C with method; boiling point only if experimentally established with pressure","Target-dependent pharmacological activity: Ki, Kd, IC50, or functional antagonist parameter, with units, target subtype, species, and assay","Material condition: Verified usable; precipitated; degraded; expired; unverified","Handling and use evidence: Applicable SDS, hazard classification, exposure-limit evidence, and dated jurisdiction-specific authorization record"]},"recognition":{"applicability":"required","items":["Identity cannot be settled by sight; preparations must be confirmed by label and pharmacy records."]},"capabilities":{"applicability":"required","items":["Resolve a ketanserin name or identifier to the parent entity and identify the supplied chemical form.","Calculate parent-equivalent amounts from verified salt stoichiometry, water content, and assay.","Assess whether a batch or prepared solution meets a specified analytical or experimental requirement.","Compare receptor evidence while retaining species, assay conditions, and competing target explanations.","Identify the material-specific handling evidence and product authorization needed for a proposed use."]},"hazards":{"applicability":"required","items":["Can prolong the QT interval and cause dangerous heart rhythms, especially with low potassium.","Lowers blood pressure and can cause dizziness or fainting."]},"interfaces":{"applicability":"required","items":["The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns ketanserin code C02KD01 among serotonin antagonists used as antihypertensives."]},"context":{"applicability":"required","items":["Ketanserin is encountered in pharmacological research investigating serotonin receptors and vascular responses.","It also appears in antihypertensive treatment literature and medicinal product records, where receptor activity must be distinguished from authorization for a particular use."]}},"sources":[{"title":"Wikidata item Q415997: ketanserin","url":"https://www.wikidata.org/wiki/Q415997","note":"identity and sense of the item"},{"title":"Wikipedia: Ketanserin","url":"https://en.wikipedia.org/wiki/Ketanserin","note":"general description of the item"}],"openQuestions":["Which verified EC identifier and jurisdiction-specific GHS classifications apply to parent ketanserin and the actual supplied form, and are any authoritative occupational exposure limits established?","Which experimentally supported melting, decomposition, pKa, solubility, and storage-stability values can be assigned to each relevant ketanserin form without transferring supplier-specific claims?","What concentration-dependent selectivity evidence distinguishes 5-HT2A antagonism from alpha-adrenergic and other target effects in the intended species and assay?","Which impurity identities and acceptance limits are justified for the intended ketanserin application, and which unresolved peaks require further characterization?","What current product authorizations and clinical safety evidence, including cardiac electrophysiology and interaction findings, govern the intended jurisdiction, route, and use?"],"resources":{"spec":"/models/things/publications/thing-q415997/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q415997/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:45:28Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:30+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}